Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy +/- Radiation Therapy in PD-L1-Negative Advanced NSCLC
NCT04929041Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2022
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival at 5 years and Overall Survival at 5 years. Started Oct 2022; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04929041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929041.